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Introduction
Cervical cancer is the second most commonly 
diagnosed malignancy and third leading cause of 
cancer-related mortality among women in less developed 
countries (Karimi Zarchi et al., 2010; Mousavi et al., 2008). 
According to GLOBOCAN, cervical cancer accounts for 
528,000 new cases and 266,000 deaths worldwide in 2012 
(Parkin et al., 2005). Although, it has been widely accepted 
for several decades that Human papillomavirus (HPV) is 
the main risk factor for development of cervical cancer 
(Behtash et al., 2009; Farbod et al., 2019; Ghaemmaghami 
et al., 2008), HPV infections have developed to persistent 
infection in only a very few cases and it is sufficient to 
induce cervical cancer in an even smaller proportion 
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(Cheng et al., 2018). Thus, many scientists acknowledge 
that etiology of cervical cancer is multifactorial and 
several factors such as sexually transmitted infections, 
reproductive factors, hormonal influences, genetics and 
host factors are responsible for development of cervical 
cancer (Momenimovahed and Salehiniya, 2017; Akhavan 
et al., 2012). However, studies revealed a preventive 
role for antiretroviral therapy (ART) on cervical lesion 
incidence and progression and promotion of regression 
(de Vries et al., 2018; Jarahzadeh et al., 2014; Jarahzadeh 
et al., 2011). In the recent years, several number of 
genome-wide association studies (GWAS) have been 
performed to evaluate the effects of different cytokines 
in development of cervical cancer, and many case-control 
studies have reported the association of IL-12 and IL-6 
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with an increased risk of cervical cancer.
IL-12 is a potent pro-inflammatory cytokine that 
plays a central role in cellular immunity which is mainly 
produced by phagocytic cells, such as dendritic cells, 
monocytes, macrophages, neutrophils, and microglia in 
response to antigenic stimulation. IL-12 has a number of 
proinflammatory biological functions and its pleiotropic 
functions which drive cellular immunity support its 
exploration as an antitumor agent. Therefore, in clinical 
studies it has been evaluated as an experimental agent 
for treatment of numerous tumours (Van Herpen et al., 
2005; Xu et al., 2004). The IL-12B gene is mapped to 
chromosome 5q31-33 and encodes the p40 subunit of 
interleukin 12 (Randolph et al., 2004). Moreover, IL-6 
is a multipotent cytokine that regulates immune and 
inflammatory responses (Aflatoonian et al., 2019b; Salimi 
et al., 2019; Sheikhpour et al., 2017). Moreover, IL-6 has 
been considered as a “metabolic hormone” which affects 
metabolism of glucose, protein and lipids (Gholami et al., 
2019). The human IL-6 gene is localized to chromosome 
7p21-24, consists of seven exons and spanning 12.8 kb 
(Salimi et al., 2019).
Up to now, many related articles have evaluated the 
association of IL-12 rs3212227 and IL-6 rs1800795 
polymorphisms with risk of cervical cancer. Some 
epidemiological studies suggested that IL-12B rs3212227 
and IL-6 rs1800795 polymorphisms are associated 
with an increased risk of cervical cancer. However, 
two recent meta-analyses were performed to evaluate 
IL-12B rs3212227 and IL-6 rs1800795 polymorphisms 
with cervical cancer risk and their results indicated 
that no significant association was found among all 
ethnicities (Chang et al., 2015; Liu et al., 2017; Pu et 
al., 2016; Zheng et al., 2017). Therefore, controversy 
and inconformity still remained about IL-12B rs3212227 
and IL-6 rs1800795 polymorphisms and most of studies 
recruited a limited sample capacity, which is insufficient 
to get a firm conclusion about the associations of these 
polymorphisms with development of cervical cancer. 
Thus, we systematically reviewed previous publications 
and a meta-analysis was conducted to evaluate the 
associations of IL-12B rs3212227 and IL-6 rs1800795 
polymorphisms with risk of cervical cancer.
Materials and Methods
Primary Search Strategy
Ethical approval was not necessary for the present 
meta-analysis. We systematically searched PubMed, 
EMBASE, Wed of Science, Elsevier, Google Scholar, 
Cochrane Library, SciELO, SID, WanFang, VIP, Chinese 
Biomedical Database (CBD) and Chinese National 
Knowledge Infrastructure (CNKI) comprehensively 
for all publications regarding the association IL-12B 
rs3212227 and IL-6 rs1800795 polymorphisms and 
cervical cancer risk up to November 10, 2019. The 
combination of following keywords and terms were used: 
(‘’Uterine Cervical Neoplasm‘’ OR ‘’Cervix Cancer’’ 
OR ‘’Cervical Cancer’’ OR ‘’Cervical Neoplasm’’ OR 
‘’Cervical Carcinoma’’) AND (‘’Interleukin 12’’ OR 
‘’IL-12’’ OR ‘’1188A>C’’ OR ‘’rs3212227’’) AND 
(‘Interleukin 6’’ OR ‘’ -174G>C’’ OR ‘’rs1800795’’) AND 
(‘‘Polymorphism’’ OR ‘‘Mutation’’ OR ‘‘Genotype’’ OR 
‘‘Allele’’ OR ‘‘Variation’’ OR ‘‘Variant’’). Meanwhile, 
hand searching of the references in retrieved reviews and 
eligible articles were performed as sources to find other 
relevant publications. Languages were limited to English, 
Portuguese, Farsi and Chinese.
Including and Excluding Criteria
We set these inclusive criteria for recruited publications: 
a) studies with case-control or cohort design; 2) published 
studies in English, Chinese and Farsi; 3) studies evaluated 
the association of IL-12B rs3212227 and IL-6 rs1800795 
polymorphisms with risk of cervical cancer; and 4) enough 
and available data to figure out odds ratios (ORs) and 95% 
confidence intervals (CIs). In addition, we also restricted 
these exclusive criteria: 1) studies without control group 
(case only studies); 2) insufficient data offered to analyze 
or unavailable data; 3) studies were carried out based 
on animals and in vitro studies; 4) studies evaluated the 
association of other polymorphisms at IL-12 and IL-6 
genes with cervical cancer; 5) case reports, case series, 
letters, comments, reviews, and previous meta-analyses 
6) overlapped data or duplication.
Data extraction
All recruited studies had to be seriously scanned 
by two individual researchers separately. If there was a 
dispute between the two researchers, they would reach a 
consensus by discussing or a third researcher. We extracted 
the following information from eligible studies: name of 
the first author, year of publication, country of origin, 
ethnicity of participants, genotyping methods, source of 
controls, total numbers of cases and controls, genotyping 
method, genotypes frequencies of cases and controls, 
minor allele frequencies (MAFs) and Hardy-Weinberg 
equilibrium test in control subjects.
Statistical Analysis
An ethical approval was not necessary as this study was 
a meta-analysis based on previous studies. The strength 
of association of IL-12B rs3212227 and IL-6 rs1800795 
polymorphisms with risk of cervical cancer was measured 
by odds ratios (ORs) with 95% confidence intervals 
(CIs). The statistical significance of the pooled OR was 
determined using the Z-test. Pooled estimates of the OR 
were obtained by calculating a weighted average of OR 
from each study. The pooled ORs was calculated under all 
five genetic models, i.e., allele (B vs. A), homozygote (BB 
vs. AA), heterozygote (BA vs. AA), dominant (BB+BA 
vs. AA) and recessive (BB vs. BA+AA). A χ2-based 
Q test was calculated for assessing the heterogeneity 
among recruited investigations and if the P-value of 
Q test exceeded 0.05 that meant there was no obvious 
heterogeneity. In addition, I2-value was used to quantify 
the proportion of the between study heterogeneity (range 
of 0 to 100%: I2=0-25%, no heterogeneity; I2=25-50%, 
moderate heterogeneity; I2= 50–75%, large heterogeneity; 
I2=75–100%, extreme heterogeneity). Random-effect 
models (DerSimonian-Laird method) would be adopted 
for analyses if I2 was >50%. Otherwise, analyses would 
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et al., 2009; Do Carmo Vasconcelos De Carvalho et al., 
2012; Han et al., 2008; Roszak et al., 2012) and seven 
studies on IL-6 rs1800795 (Gangwar et al., 2009; Grimm 
et al., 2011; Nogueira De Souza et al., 2006; Pu et al., 
2016; Shi et al., 2013; Zidi et al., 2017) were selected. 
Characteristics of included studies are shown in Table 1. 
All eligible studies were published in English and Chinese 
between April, 2008 and November, 2017. Among them, 
five studies were based on Asians, three studies based on 
mixed populations, two studies based on Caucasians, and 
one study was based on African populations. The selected 
studies were conducted in Korea, China, Brazil, Poland, 
India, Austria and Tunisia. Five different genotyping 
methods including SNaPShot, PCR-RFLP, direct 
Sequencing, TaqMan and qRT-PCR were used by selected 
studies. The allele, genotype and minor allele frequency 
(MAF) distributions in the cases and controls are shown 
in Table 1. Moreover, the distribution of genotypes in 
the controls was in agreement with Hardy-Weinberg 
equilibrium (HWE) for all selected studies, except for 
two studies on IL-6 rs1800795 polymorphism (Table 1).
Quantitative Data Synthesis
IL-12B rs3212227 Polymorphism
The summary of the meta-analysis of the association 
of between IL-12B rs3212227 polymorphism and cervical 
cancer risk are shown in Table 2. Overall, there was 
be conducted with fixed-effect models (Mantel- Haenszel 
method). Genotype frequencies of controls for each study 
using goodness-of-fit test (chi-square) and a p-value less 
than 0.05 was considered as significant disequilibrium 
(HWE-violating). Sensitivity analysis was conducted by 
excluding one study at a time to examine the stability 
of the pooled results. Begg’s funnel plot and Egger’s 
linear regression test were applied to assess potential 
publication bias, in which P<0.05 was considered 
statistically significant. All of the statistical calculations 
were performed using Comprehensive Meta-Analysis 
(CMA) software version 2.0 (Biostat, USA). Two-sided 
P-values < 0.05 were considered statistically significant.
Results
Characteristics of Included Studies
By electronic and manual searches concerning the 
association of IL-12B rs3212227 and IL-6 rs1800795 
polymorphisms and cervical cancer risk, 297 relevant 
studies up to November 05, 2019 were identified. After 
reading titles and abstracts, 139 irrelevant and duplicate 
articles were excluded. Another 95 articles were 
subsequently excluded because not reporting useful data 
for meta-analysis, review, case only study, and not being 
case-control studies. Finally, a total of eleven case-control 
studies including four studies on IL-12B rs3212227 (Chen 
Figure 1. Flow Chart for the Process of Selecting Eligible Studies
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no significant association between IL-12B rs3212227 
polymorphism and cervical cancer risk under all five 
genetic models genetic models, i.e., allele (C vs. A: OR 
= 1.076, 95% CI 0.783-1.479, p=0.651, Figure 2A), 
homozygote (CC vs. AA: OR = 1.330, 95% CI 0.988-1.790, 
p=0.060), heterozygote (CA vs. AA: OR = 1.119, 95% CI 
0.696-1.800, p=0.643), dominant (CC+CA vs. AA: OR = 
1.125, 95% CI 0.704-1.799, p =0.623, Fig2B), recessive 
(CC vs. CA+AA: OR = 1.140, 95% CI 0.874-1.487, p 
=0.333). However, subgroup analysis by ethnicity showed 
a significant association between IL-12B rs3212227 
polymorphism and an increased risk of cervical cancer 
in Asian women (CA vs. AA: OR = 1.349, 95% CI 
1.032-1.762, p=0.028 and CC+CA vs. AA: OR = 1.340, 
95% CI 1.041-1.725, p =0.023, Table 2).
IL-6 rs1800795 Polymorphism
The summary of the meta-analysis of the association 
of between IL-6 rs1800795 polymorphism and cervical 
cancer risk are shown in Table 2. Pooled ORs revealed 
that IL-6 rs1800795 polymorphism was significantly 
associated with an increased risk of cervical cancer under 
four genetic models, i.e., allele (C vs. G: OR = 1.294, 
95% CI 1.071-1.564, p= 0.007, Figure 2C), homozygote 
(CC vs. GG: OR = 1.633, 95% CI 1.059-2.520, p= 
0.027), dominant (CC+CG vs. GG: OR = 1.312, 95% CI 
1.048-1.643, p= 0.018) and recessive (CC vs. CG+GG: 
OR = 1.592, 95% CI 1.268-1.999, p≤0.001, Figure 2D). 
Moreover, subgroup analysis by ethnicity revealed an 
increased risk of cervical cancer in Asian women. When 
stratified by country of origin, there was a significant 
association between IL-6 rs1800795 polymorphism and 
cervical cancer risk among Chinese women (C vs. G: 
OR = 1.422, 95% CI 1.025-1.971, p= 0.035; CC vs. GG: 
OR = 1.851, 95% CI 1.377-2.488, p≤0.001; and CC vs. 
CG+GG: OR = 1.641, 95% CI 1.251-2.151, p≤0.001), but 
not among Brazilian women (Table 2).
Between-Study Heterogeneity Test
As shown in Table 2, there was significant 
between-study heterogeneity under almost genetic 
models for both IL-12B rs3212227 and IL-6 rs1800795 
polymorphisms in the overall population. To explore the 
potential sources of heterogeneity, subgroup analyses by 
ethnicity, country of origin and HWE was performed. The 
results suggested that ethnicity might be contributed to 
between-study heterogeneity in the current meta-analysis.
Sensitivity Analysis
A sensitivity analysis was used to test the effects of 
each study on pooled ORs. There were no significant 
differences observed upon removal of any of the 
studies, suggesting that our findings were statistically 
robust and reliable. Moreover, we performed sensitivity 
analysis by excluding those HWE-violating studies 
for IL-6 rs1800795. However, after excluding those 
studies the pooled ORs were not changed statically in 
the overall population, indicating that this meta-analysis 
result were statistically robust and reliable.
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Publication Bias
Begg’s funnel  plot  and Egger ’s test  were 
inspected to evaluate the possible publication bias in 
this meta-analysis. The shape of the funnel did not 
show any obvious asymmetry under all five genetic 
models for both IL-12B rs3212227 and IL-6 rs1800795 
polymorphisms (Figure 3). Moreover, Egger’s test was 
statistically revealed that there was no a significant bias 
for IL-12B rs3212227 polymorphism (C vs. A: PBeggs 
= 0.308; PEggers = 0.236; CC vs. AA: PBeggs = 0.734, 
PEggers = 0.782; CA vs. AA: PBeggs = 0.308, PEggers = 
0.356; CC+CA vs. AA: PBeggs = 0.308, PEggers = 0.317; and 
CC vs. CA+AA: PBeggs = 0.734, PEggers = 0.946) and IL-6 
rs1800795  polymorphism (C vs. G: PBeggs = 0.763, PEggers 
= 0.701; CC vs. GG: PBeggs = 0.763, PEggers = 0.587; CG 
vs. GG: PBeggs = 0.763, PEggers = 0.728; CC+CG vs. GG: 
PBeggs = 1.000, PEggers = 0.583; and CC vs. CG+GG: 
PBeggs = 0.548, PEggers = 0.646).
Discussion
Our pooled data showed that IL-12B rs3212227 
polymorphism was not significantly associated with an 
increased risk of cervical cancer. However, our subgroup 
Subgroup Genetic Model Type of 
Model
Heterogeneity Odds Ratio Publication Bias
I2 (%) PH OR 95% CI Ztest POR PBeggs PEggers
IL-12B rs3212227
Overall Population C vs. A Random 81.69 0.001 1.076 0.783-1.479 0.452 0.651 0.308 0.236
CC vs. AA Random 54.75 0.085 1.33 0.988-1.790 1.878 0.06 0.734 0.782
CA vs. AA Random 82.52 0.001 1.119 0.696-1.800 0.463 0.643 0.308 0.356
CC+CA vs. AA Random 83.68 ≤0.001 1.125 0.704-1.799 0.492 0.623 0.308 0.317
CC vs. CA+AA Random 24.76 0.263 1.14 0.874-1.487 0.969 0.333 0.734 0.946
Asians C vs. A Fixed 0 0.87 1.166 0.988-1.377 1.812 0.07 NA NA
CC vs. AA Fixed 0 0.932 1.323 0.941-1.860 1.61 0.107 NA NA
CA vs. AA Fixed 0 0.454 1.349 1.032-1.762 2.191 0.028 NA NA
CC+CA vs. AA Fixed 0 0.594 1.34 1.041-1.725 2.271 0.023 NA NA
CC vs. CA+AA Fixed 0 0.507 1.086 0.807-1.461 0.542 0.588 NA NA
IL-6 rs1800795 
Overall Population C vs. G Random 60 0.02 1.294 1.071-1.564 2.675 0.007 0.763 0.701
CC vs. GG Random 54.07 0.042 1.633 1.059-2.520 2.217 0.027 0.763 0.587
CG vs. GG Random 52.47 0.049 1.232 0.971-1.562 1.718 0.086 0.763 0.728
CC+CG vs. GG Random 53.01 0.047 1.312 1.048-1.643 2.371 0.018 1 0.583
CC vs. CG+GG Fixed 48.97 0.068 1.592 1.268-1.999 3.999 ≤0.001 0.548 0.646
Asians C vs. G Fixed 65.97 0.053 1.395 1.230-1.582 5.195 ≤0.001 1 0.793
CC vs. GG Fixed 56.74 0.099 1.951 1.472-2.584 4.656 ≤0.001 1 0.375
CG vs. GG Fixed 66.54 0.05 1.289 1.077-1.543 2.769 0.006 1 0.613
CC+CG vs. GG Fixed 61 0.077 1.429 1.207-1.692 4.136 ≤0.001 1 0.766
CC vs. CG+GG Fixed 53.87 0.114 1.736 1.339-2.251 4.166 ≤0.001 0.296 0.205
By Country
China C vs. G Random 82.88 0.016 1.422 1.025-1.971 2.111 0.035 NA NA
CC vs. GG Fixed 70.12 0.067 1.851 1.377-2.488 4.083 ≤0.001 NA NA
CG vs. GG Random 75.83 0.042 1.351 0.912-1.999 1.502 0.133 NA NA
CC+CG vs. GG Random 77.92 0.033 1.466 0.994-2.162 1.929 0.054 NA NA
CC vs. CG+GG Fixed 56.13 0.131 1.641 1.251-2.151 3.581 ≤0.001 NA NA
Brazil C vs. G Random 77.49 0.035 1.043 0.534-2.307 0.123 0.902 NA NA
CC vs. GG Fixed 0 0.568 0.385 0.127-1.164 -1.691 0.091 NA NA
CG vs. GG Fixed 62.94 0.1 1.356 0.905-2.032 1.474 0.14 NA NA
CC+CG vs. GG Fixed 75.47 0.043 1.239 0.559-2.748 0.528 0.598 NA NA
CC vs. CG+GG Fixed 0 0.704 0.37 0.124-1.105 -1.781 0.075 NA NA
HWE* C vs. G Random 71.99 0.006 1.239 0.979-1.564 1.783 0.075 0.806 0.451
CC vs. GG Random 68.89 0.012 1.633 0.978-2.727 1.876 0.061 0.806 0.682
CG vs. GG Fixed 57.83 0.05 1.198 1.019-1.407 2.194 0.028 0.462 0.18
CC+CG vs. GG Random 63.28 0.028 1.213 0.928-1.587 1.412 0.158 0.22 0.163
CC vs. CG+GG Random 64.82 0.023 1.588 1.004-2.510 1.977 0.048 1 0.827
Table 2. Summary Risk Estimates for Association of IL-12B rs3212227 and IL-6 rs1800795 Polymorphisms with 
Cervical Cancer Risk
NA, Not Applicable; *, By excluding HWE-violating studies 
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analysis revealed that IL-12B rs3212227 polymorphism 
was significantly associated with risk of cervical cancer in 
Asians. Roszak et al., in a case-control study reported that 
the IL-12B rs3212227 might be contributed to an increased 
risk of cervical cancer in Polish population. However, de 
Carvalho et al., (2012) reported that IL-12B rs3212227 
polymorphism has a protective effect in development of 
cervical cancer among Brazil women. Moreover, Han et 
al., (2008) in an earlier study identified that there was 
no relationship between cervical cancer and IL-12B 
rs3212227 in Korean population. In 2017, Zheng et 
al., (2017) in a meta-analysis of 33 studies with 10,587 
cancer cases and 12,040 cancer-free controls evaluated 
association of IL-12B rs3212227 with cancer risk. Their 
pooled data showed a significant association between 
IL-12B rs3212227 polymorphisms and overall cancer risk, 
Figure 2. Forest Plot for the Association of IL-12B rs3212227 and IL-6 rs1800795 Polymorphisms with Risk of 
Cervical Cancer in the Overall Population. A, IL-12B rs3212227 (allele model: C vs. A); B, IL-12B rs3212227 
(dominant model: CC+CA vs. AA); C, IL-6 rs1800795 (allele model: C vs. G); D, IL-6 rs1800795 (recessive model: 
CC vs. CG+GG).
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especially in hepatocellular carcinoma, nasopharyngeal 
cancer, and among Asians. However, their stratification 
analyses demonstrated that IL-12B rs3212227 was not 
associated with cervical cancer. In 2015, Chang et al., 
(2015) in a meta-analysis of five case-control studies with 
2,552 cases and 2,232 controls were evaluated association 
of IL-12B rs3212227 with cervical cancer. Their results 
revealed that rs3212227 polymorphism in IL-12 gene may 
not be the risk factor to cervical cancer.
In 2006, Nogueira De Souza et al., (2006) for first 
time in a case-control study with 56 cases and 253 
controls evaluated the association of IL-6 rs1800795 
polymorphism with cervical cancer in a Brazilian 
population. Since a few studies evaluated the association 
in different population. Our pooled data revealed that 
IL-6 rs1800795 polymorphism was associated with an 
increased risk of cervical cancer in the overall population. 
Similarly, Duan et al., (2018) in a meta-analysis of seven 
publications found that IL-6 rs1800795 polymorphism 
was associated with cervical cancer risk. In 2017, Zidi et 
al., (2017) in a case-control study evaluated the effects 
of IL-6 rs2069845, rs2069840, rs1474348, rs1800795, 
rs1800797, and rs2069827 polymorphisms with risk of 
cervical cancer among Tunisian women. Their results 
revealed high linkage disequilibrium (LD) between 
rs2069845, rs2069840, rs1474348, and rs1800795 
polymorphism. Moreover, their 6-locus haplotype analysis 
have identified that GACCCA haplotype to be positively 
associated with an increased risk of cervical cancer, while 
GAGGGG haplotype was negatively associated with 
occurrence of cervical cancer, thus suggesting a protective 
role for this haplotype in development of this disease. 
They have reported that IL-6 rs1800795 polymorphism 
might be has a protective role in development of cervical 
cancer. In 2016, Pu et al., (2016) in a case-control study 
of 360 cervical cancer cases and 728 controls evaluated 
the relationship between rs1800795 and rs2069837 
polymorphisms at IL-6 and cervical cancer among Chinese 
women. Their results revealed that mutant alleles of 
rs1800795 and rs2069837 polymorphisms were associated 
with an increased risk cervical cancer. de Lima et al., 
(2016) revealed that there was no significant association 
between the IL-6 rs1800795 polymorphism and HPV 
infected women or uninfected controls. Moreover, they 
have not found any significant association between 
TGF-β1 +869T>C and +915G>C polymorphisms and 
the risk of HPV infection in the patients. Thus, they have 
hypothesized that the IL-6 rs1800795 polymorphism did 
Figure 3. Begg’s Funnel Plot for the Association of IL-12B rs3212227 and IL-6 rs1800795 Polymorphisms with Risk 
of Cervical Cancer. A, IL-12B rs3212227 (allele model: C vs. A); B, IL-6 rs1800795 (dominant model: CC+CG vs. 
GG).
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not play a role in the risk of HPV infection in the Brazilian 
population .
Between-study Heterogeneity in a meta-analysis 
refers to the variation in study outcomes between studies 
(Bahrami et al., 2019; Yazdi et al., 2017). Moreover, the 
extent to which effect sizes vary within a meta-analysis 
is called heterogeneity. Heterogeneity is to be expected 
in a meta-analysis and assessment of heterogeneity. 
Thus, the proportion of between-study heterogeneity 
is one of the major concerns in meta-analysis because 
nonhomogeneous study has high possibility to mislead 
results (Gohari et al., 2019). Therefore, the assessment 
of heterogeneity is necessary, as high heterogeneity could 
be caused by the fact that there are actually two or more 
subgroups of studies present in the data, which have a 
different true effect. According to our previous meta-
analyses, we suggested that heterogeneity might be due 
to differences in study design, sample size, genotyping 
methods, disease heterogeneity, and to the different roles 
played by gene-gene and gene-environment interactions 
(Aflatoonian et al., 2019a; Mirjalili et al., 2018; 
Moghimi et al., 2019, 2018). Moreover, after subgroup 
an analysis, heterogeneity was obviously decreased in 
Asians; however, the corresponding pooled ORs were not 
materially altered after deleting these studies, indicating 
that our results were statistically robust. Publication 
bias is another key factor that might affect the quality 
of a meta-analysis (Niktabar et al., 2019; Veisian et al., 
2019). Both Begg’s and Egger’s test were used to assess 
publication bias in this study. No significant publication 
bias was observed when all studies were included.
Several limitations should be acknowledged for 
interpretation of our pooled ORs. First, in the current 
meta-analysis we have selected only eligible published 
articles, so some relevant unpublished studies might be 
missed, generating certain publication bias, though not 
detected even with funnel plot or Egger test. Second, 
the sample size for both IL-12B rs3212227 and IL-6 
rs1800795 polymorphisms was relatively small, with 
limited statistical power to explore the associations. Third, 
included studies are still so limited that we cannot perform 
subgroup analysis by ethnicity, genotyping methods 
and source of controls. Accordingly, it is required that 
a more precise analysis could be performed if sufficient 
individual study in globally populations were available. 
Fourth, there was heterogeneity between studies for both 
IL-12B rs3212227 and IL-6 rs1800795 polymorphisms 
which could distort our pooled data. Fifth, due to lack 
of original data in the selected studies restricted us to 
continue investigating some potential interactions, such 
as age, HPV infection, reproductive factors, hormonal 
influences, family history, environmental factors, and 
lifestyle. Hence, our pooled ORs might have some bias 
to a certain degree. Finally, cervical cancer is a complex 
disease with etiological factors that can be subdivided 
into extrinsic and intrinsic factors, whereas, in the 
current meta-analysis, the effects of these factors were 
not performed due to the insufficient data. Furthermore, 
plausible effects of gene-gene and gene-environment 
interactions on development of cervical cancer risk were 
not taken into account because of limited data as well.
In summary, our pooled data revealed that IL-12B 
rs3212227 and IL-6 rs1800795 polymorphisms could 
be used to identify individuals at high risk of cervical 
cancer in Asian women. In view of the above mentioned 
restrictions, high-quality researches with larger sample 
sizes are needed to assess the effect among different 
ethnicities and to validate our results.
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